Kura Oncology reports positive top-line results from a phase two trial for tipifarnib.
M2 PHARMA-September 11, 2017-Kura Oncology reports positive top-line results from a phase two trial for tipifarnib
(C)2017 M2 COMMUNICATIONS
United States-based Kura Oncology, a clinical stage biopharmaceutical company, has reported positive top-line results from a phase two trial for its lead product candidate, tipifarnib, intended for the treatment of HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC), it was reported on Friday.
The Phase two trial achieved its primary endpoint prior to the completion of enrolment.
The trial protocol requires four confirmed, partial responses, per RECIST 1.1 criteria, out of 18 patients to meet its primary endpoint. Four confirmed, partial responses and two patients with disease stabilisation were observed from the first six evaluable HNSCC patients enrolled in the trial. In addition, objective responses greater than one year in duration have already been observed in two patients. All patients joined the study upon progression while undertaking prior therapy, including chemotherapy, cetuximab or immune therapy.
The company will continue to enrol HRAS mutant HNSCC patients and plans to present data from the study at an upcoming scientific or medical conference.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 11, 2017|
|Previous Article:||Gecko Biomedical granted CE Mark approval for its SETALUM Sealant.|
|Next Article:||Regeneron and Sanofi partnership awarded US FDA breakthrough therapy designation for cemiplimab for squamous cell carcinoma.|